Christina Wang Epstein
Internal Medicine · Somerset, NJNPI 1861591984
Payments from drug & device makers
Across 230 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$638
- Novo Nordisk$360
- Lilly USA, LLC$342
- Amgen$304
- Eisai Inc.$186
- Johnson & Johnson$179
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,641100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 41 | $638 |
| Novo Nordisk | 24 | $360 |
| Lilly USA, LLC | 20 | $342 |
| Amgen | 20 | $304 |
| Eisai Inc. | 11 | $186 |
| Johnson & Johnson | 13 | $179 |
| GSK | 10 | $153 |
| Boehringer Ingelheim | 10 | $145 |
| Abbott | 6 | $111 |
| Exact Sciences | 6 | $108 |
| Merck | 7 | $102 |
| Corcept Therapeutics | 5 | $94 |
| Sanofi Pasteur Inc. | 5 | $90 |
| Pfizer | 6 | $90 |
| Sumitomo Pharma America, Inc. | 5 | $89 |
| AbbVie(2 entities) | 6 | $89 |
| Daiichi Sankyo Inc. | 4 | $59 |
| Kowa Pharmaceuticals America, Inc. | 4 | $57 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Medtronic(2 entities) | 2 | $45 |
| Boston Scientific | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Nevro Corp. | 2 | $29 |
| Bayer | 1 | $23 |
| Novartis | 1 | $22 |
| Baxter Healthcare | 1 | $22 |
| Echosens North America, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Biogen | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Watermark Medical, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Acarix USA Inc. | 1 | $12 |
How this compares
$3,641 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $118,691 |
| MounjaroTirzepatide | 90 | $106,153 |
| JardianceEmpagliflozin | 57 | $66,186 |
| JanuviaSitagliptin Phosphate | 59 | $61,494 |
| TrulicityDulaglutide | 43 | $51,259 |
| EliquisApixaban | 47 | $49,996 |
| FarxigaDapagliflozin Propanediol | 30 | $40,229 |
| Repatha SureclickEvolocumab | 16 | $14,898 |
| Repatha PushtronexEvolocumab | 16 | $14,834 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $7,284 |
| Atorvastatin Calcium | 589 | $5,635 |
| Rosuvastatin Calcium | 201 | $5,321 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $4,211 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,996 |
| Amlodipine Besylate | 442 | $3,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $342 | $157,412133 claims |
| Novo NordiskOzempic | $360 | $118,69198 claims |
| Boehringer IngelheimJardiance | $145 | $66,18657 claims |
| MerckJanuvia | $102 | $61,49459 claims |
| PfizerEliquis | $90 | $49,99647 claims |
| AstraZenecaFarxiga | $638 | $40,22930 claims |
| AbbVieSynthroid | $89 | $2,21638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Somerset
- Devraj LahiriSomerset$695K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.